Trump-Era Drug Pricing Agreements: A Retrospective
During his presidency, Donald Trump pursued a strategy of directly negotiating drug prices with pharmaceutical companies, aiming to lower costs for American consumers. This effort involved securing voluntary agreements with manufacturers to limit price increases or roll back planned hikes. Here’s a look at the key developments and outcomes of these agreements:
in September 2020, the Trump administration announced nine agreements with major pharmaceutical companies, including Pfizer, Merck, Johnson & Johnson, and others, to limit price increases on a range of prescription drugs [1].These agreements followed executive orders issued earlier that year designed to tie Medicare drug prices to those paid in other developed countries.
Specifically, the agreements involved commitments from the companies to postpone planned price increases for the remainder of 2020 and, in some cases, to roll back previously announced increases. The administration touted these deals as a important win for patients, potentially saving billions of dollars. Though, critics pointed out that the agreements were voluntary and lacked enforcement mechanisms [2].
Further bolstering this effort, in January 2021, Johnson & Johnson reached an agreement to bring the total number of pharmaceutical companies participating in Trump’s drug-pricing effort to 15 out of 17 major companies [3].
Impact and Subsequent Developments:
The long-term impact of these agreements remains a subject of debate. While the immediate effect was to delay or prevent some price increases, the voluntary nature of the deals meant they were not legally binding and could be altered or abandoned by the companies at any time.
With the change in administration in January 2021,the Biden administration shifted its approach to drug pricing,focusing on legislative solutions such as allowing Medicare to negotiate drug prices directly with manufacturers,a provision included in the Inflation Reduction Act of 2022 [4].This legislation represents a significant departure from the Trump administration’s reliance on voluntary agreements.
Sources:
[1] https://www.ajmc.com/view/trump-strikes-9-new-pricing-agreements-as-drugmakers-navigate-tariff-regulatory-pressure
[2] https://www.kff.org/policy-watch/trump-administration-drug-pricing-agreements-what-to-know/
[3] https://www.ajmc.com/view/j-j-agreement-brings-15-of-17-pharma-companies-into-trump-s-drug-pricing-effort
[4] https://www.cms.gov/newsroom/fact-sheets/inflation-reduction-act-lowering-prescription-drug-costs-americans
Keep reading